MAH Collection Pte. Ltd. is an approved licencee by HeiQ for the auccessful appliction of NPJ03 Viroblock to textile materials such as silk, cotton and silk/cotton mix fabrics.
HeiQ Viroblock NPJ03 is an intelligent Swiss textile technology that is added to the fabric during the final stage of the textile manufacturing process.
TESTED EFFECTIVE AGAINST SARS-COV-2 (COVID-19)
HeiQ Viroblock NPJ03 has been tested effective 99.99% in 30 minutes against SARS-CoV-2,the COVID-19 causing virus
Residual virus infectivity tested according to a modified ISO 20743 method (Sendai virus), rapid antiviral effect demonstrated within 2-5 minutes
Tested according to ISO 18184 as strong antiviral and ISO 20743 as strong antibacterial against enveloped viruses and bacteria
Certified as safe and sustainable as all its ingredients are cosmetic grade, bio-based (72% bio-based carbon (4), 26% hydrocarbon, 2% microsilver)
HeiQ Viroblock Technology was developed at first for the Ebola crisis in 2013. The medical class 1 FFP2 masks used during the crisis in Africa have recently been tested again. The antimicrobial performance was unchanged after 7 years of shelf-life
HeiQ won the prestigious Swiss Technology Award 2020 for HeiQ Viroblock
EU REACH and US FIFRA compliant, OEKOTEX® certified, ZDHC and bluesign® homologized
Treated textile articles are compliant with EU BPR and US EPA
For washable fabrics: Lasts at least 30 gentle washes at 60°C (140°F) ((ISO 6330 6G)
provides a self-sanitizing and germ resistant surface
HeiQ Viroblock NPJ03 is among the first textile technologies in the world to be proven effective against SARS-CoV-2 in the laboratory. Tests conducted by Swiss textile innovator HeiQ with the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia (Doherty Institute) showed that treated fabric demonstrated rapid antiviral action against the SARS-CoV-2 virus strain.
HeiQ Viroblock NPJ03 is a textile treatment designed to provide textiles with antiviral and antibacterial properties. The combination of silver antimicrobial technology and vesicle technology rapidly destroy enveloped viruses including coronaviruses. It has previously been tested against coronavirus 229E, another strain of virus in the Coronavirus family.
The latest testing with SARS-CoV-2 virus was conducted by researchers at the Doherty Institute, a joint venture between the University of Melbourne and The Royal Melbourne Hospital, an internationally renowned institution combining research, teaching, public health and reference laboratory services, diagnostic services and clinical care into infectious diseases and immunity.
The research project involved a disinfection test protocol that simulated the real-life interaction of small aerosol droplets contaminating clothing. A known concentration of SARS-CoV-2 virus was contacted with the sample fabric for 30 minutes followed by measurement of remaining infectious SARS-CoV-2 viruses.
The fabric sample treated with HeiQ Viroblock NPJ03 had no infective viruses left after 30 minutes. The result indicated a SARS-CoV-2 virus reduction of over 99.9% relative to the inoculum control.
About the Doherty Institute
Finding solutions to prevent, treat and cure infectious diseases and understanding the complexities of microbes and the immune system requires innovative approaches and concentrated effort. This is why the University of Melbourne – a world leader in education, teaching and research excellence – and The Royal Melbourne Hospital – an internationally renowned institution providing outstanding care, research and learning – partnered to create the Peter Doherty Institute for Infection and Immunity (Doherty Institute); a centre of excellence where leading scientists and clinicians collaborate to improve human health globally.